IL6 and type 2 diabetes mellitus: Furthermore components of NLRP3 inflammasome and downstream signalling pathways are potential novel targets for pharmacological prevention of late complications of T2D [36], as clinical trials targeting other inflammatory cytokines such as IL-6 and TNFa have not been successful [37, 38].